PL1711531T3 - Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania - Google Patents
Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowaniaInfo
- Publication number
- PL1711531T3 PL1711531T3 PL04817634T PL04817634T PL1711531T3 PL 1711531 T3 PL1711531 T3 PL 1711531T3 PL 04817634 T PL04817634 T PL 04817634T PL 04817634 T PL04817634 T PL 04817634T PL 1711531 T3 PL1711531 T3 PL 1711531T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- antibodies
- tlr4
- neutralizing anti
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52881203P | 2003-12-10 | 2003-12-10 | |
US52881103P | 2003-12-10 | 2003-12-10 | |
US52896203P | 2003-12-10 | 2003-12-10 | |
PCT/IB2004/004433 WO2005065015A2 (en) | 2003-12-10 | 2004-12-10 | Neutralizing antibodies and methods of use thereof |
EP04817634A EP1711531B9 (en) | 2003-12-10 | 2004-12-10 | Neutralizing anti tlr4/md-2 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1711531T3 true PL1711531T3 (pl) | 2012-07-31 |
Family
ID=34753681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04817634T PL1711531T3 (pl) | 2003-12-10 | 2004-12-10 | Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1711531B9 (pl) |
JP (1) | JP4762152B2 (pl) |
AT (1) | ATE544783T1 (pl) |
AU (1) | AU2004311541B2 (pl) |
CA (1) | CA2548990C (pl) |
DK (1) | DK1711531T3 (pl) |
ES (1) | ES2382039T3 (pl) |
PL (1) | PL1711531T3 (pl) |
PT (1) | PT1711531E (pl) |
WO (1) | WO2005065015A2 (pl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
US7674884B2 (en) | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
EP1830881B1 (en) * | 2004-12-10 | 2010-06-02 | NovImmune SA | Combining therapies targeting multiple toll-like receptors and use thereof |
BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
GB0620705D0 (en) | 2006-10-18 | 2006-11-29 | Opsona Therapeutics | Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds |
CA2689680C (en) * | 2007-05-14 | 2017-11-07 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
US8669113B2 (en) | 2008-04-03 | 2014-03-11 | Becton, Dickinson And Company | Advanced detection of sepsis |
CA2824060C (en) | 2011-01-10 | 2021-05-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
HUE037613T2 (hu) | 2012-03-29 | 2018-09-28 | Novimmune Sa | Anti-TLR4 antitestek és azok felhasználása |
US9688769B2 (en) * | 2013-10-22 | 2017-06-27 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
US10689441B2 (en) | 2013-12-06 | 2020-06-23 | Novimmune Sa | Anti—TLR4 antibodies and methods of use thereof |
JP6579097B2 (ja) | 2014-02-28 | 2019-09-25 | アステラス製薬株式会社 | 新規ヒトtlr2及びヒトtlr4に結合する二重特異的抗体 |
KR101745520B1 (ko) * | 2015-05-29 | 2017-06-12 | 아주대학교산학협력단 | 신규한 tlr4 길항제 |
EP3534960A4 (en) * | 2016-11-07 | 2020-05-13 | Coimmune, Inc. | BISPECIFIC ANTIBODIES THAT MODULATE TLR-4 SIGNALING AND THEIR USES |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
-
2004
- 2004-12-10 JP JP2006543665A patent/JP4762152B2/ja active Active
- 2004-12-10 PT PT04817634T patent/PT1711531E/pt unknown
- 2004-12-10 DK DK04817634.1T patent/DK1711531T3/da active
- 2004-12-10 EP EP04817634A patent/EP1711531B9/en active Active
- 2004-12-10 ES ES04817634T patent/ES2382039T3/es active Active
- 2004-12-10 AT AT04817634T patent/ATE544783T1/de active
- 2004-12-10 AU AU2004311541A patent/AU2004311541B2/en active Active
- 2004-12-10 WO PCT/IB2004/004433 patent/WO2005065015A2/en active Application Filing
- 2004-12-10 PL PL04817634T patent/PL1711531T3/pl unknown
- 2004-12-10 CA CA2548990A patent/CA2548990C/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2004311541B2 (en) | 2011-06-30 |
EP1711531B9 (en) | 2012-07-25 |
CA2548990A1 (en) | 2005-07-21 |
ATE544783T1 (de) | 2012-02-15 |
ES2382039T3 (es) | 2012-06-04 |
DK1711531T3 (da) | 2012-04-30 |
PT1711531E (pt) | 2012-04-18 |
AU2004311541A1 (en) | 2005-07-21 |
WO2005065015A3 (en) | 2005-12-01 |
EP1711531A2 (en) | 2006-10-18 |
JP2007517503A (ja) | 2007-07-05 |
WO2005065015A2 (en) | 2005-07-21 |
EP1711531B1 (en) | 2012-02-08 |
JP4762152B2 (ja) | 2011-08-31 |
CA2548990C (en) | 2014-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007110678A3 (en) | Neutralizing antibodies and methods of use thereof | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
PL1711531T3 (pl) | Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
TW200616662A (en) | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates | |
WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
WO2007027805A3 (en) | Method for generating anti-variable region monoclonal antibodies | |
UA104132C2 (en) | Humanized antibodies against tl1a | |
UA94576C2 (ru) | Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител | |
RS80704A (en) | ANTI- av?6.ANTIBODIES | |
WO2005012493A3 (en) | Anti-cd19 antibodies | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
MX2010002683A (es) | Poblaciones de anticuerpos homogeneos. | |
WO2005121179A3 (en) | Transferrin receptor antibodies | |
WO2008066691A3 (en) | Tes7 and antibodies that bind thereto | |
WO2004005470A3 (en) | Antibodies to non-shed muc1 and muc16, and uses thereof | |
TW200700081A (en) | Anti-ctla-4 antibody compositions | |
IL197459A0 (en) | Humanized proteins, including antibodies and methods for producing the same | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
WO2003034903A3 (en) | Psma antibodies and protein multimers | |
WO2005113000A3 (en) | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |